Compare Intuit Inc. (INTU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Merck & Co., Inc. — how do they compare? Intuit Inc. trades at $279.51 (market cap $80.37B), while Merck & Co., Inc. trades at $124.78 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 3.8× Intuit Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| INTU | MRK | |
|---|---|---|
Market Cap | $80.37B | $307.25B |
Sector | Technology | Health |
52-Week High | $807.39 | $129.52 |
52-Week Low | $255.07 | $77.60 |
Enterprise Value | $78.83B | $350.66B |
Dividend Yield | 1.63% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $293.82, up 0.94% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. The stock faces headwinds from legal investigations into pricing disclosures, contributing to a 20% drop from 2025 highs, but maintains a consensus analyst price target of $423.11 with 71% buy ratings.
The outlook is mixed: strong revenue growth and AI-driven product expansion support upside, but legal risks and competitive pressures pose significant threats. Investors should weigh the company's solid financials against ongoing litigation and market sentiment shifts for balanced risk-reward assessment.
Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
